Private equity: where we have been and the road ahead

I-36: Preimplantation Genetic Diagnosis - Where Have We Been and Where Are We Going

Preimplantation genetic diagnosis (PGD) is now considered routine in IVF laboratories with micromanipulation capability and access to genetic diagnostic services. The past two decades have witnessed a dramatic increase in the use of PGD, the number of cycles performed, and the indications for which PGD has been used. This increase has been mirrored by a slow, but steady, increase in the range o...

Where we have been, where we are going.

Revisiting the diagnosis of schizophrenia: where have we been and where are we going?

Appropriate and reliable classification of mental illness is crucial for advancing the field of psychiatry as agreement on diagnosis has broad implications for treatment of mental disorders and research into the etiopathophysiology of mental disorders. Since schizophrenia was first recognized by Kraepelin (as dementia praecox), there has been much discussion about what does and does not diagnos...

The obesity pandemic: where have we been and where are we going?

Obesity, a new pandemic, is associated with an increased risk of death, morbidity, and accelerated aging. The multiple therapeutic modalities used to promote weight loss are outlined with caution, especially for patients who are very young or old. Except for very rare single gene defects, the inheritance of obesity is complex and still poorly understood, despite active investigations. Recent ad...

Exercise and Duchenne muscular dystrophy: where we have been and where we need to go.

EXERCISE AND DUCHENNE MUSCULAR DYSTROPHY: WHERE WE HAVE BEEN AND WHERE WE NEED TO GO CHAD D. MARKERT, PhD, LAURA E. CASE, DPT, PCS, GREGORY T. CARTER, MD, MS, PATRICIA A. FURLONG, RN, BSN, MS, and ROBERT W. GRANGE, PhD Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, North Carolina 27157, USA Division of Physical Therapy, Department of Community and Family...